Our study demonstrates that patients with thyroid nodules assigned to category IV taking thyroid hormone therapy in non-suppressive doses might be monitored for longer periods of time without surgical treatment than those who are not receiving this therapy. This evidence concerns the gene TG and thyroid nodule.